NASDAQ:SLS SELLAS Life Sciences Group Q1 2026 Earnings Report $7.78 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.78 0.00 (0.00%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast SELLAS Life Sciences Group EPS ResultsActual EPS-$0.05Consensus EPS -$0.06Beat/MissBeat by +$0.01One Year Ago EPSN/ASELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASELLAS Life Sciences Group Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsSELLAS Life Sciences Group's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SELLAS Life Sciences Group Earnings HeadlinesSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomesMay 20, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSLS stock rallies after hours as CEO teases leukemia study data any day nowMay 19, 2026 | msn.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells. The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1. GPS is currently being evaluated in ongoing Phase II/III clinical trials for acute myeloid leukemia (AML), malignant pleural mesothelioma and ovarian cancer. SELLAS is also exploring combination regimens of GPS with immune checkpoint inhibitors to enhance antitumor activity, as well as next-generation cellular approaches intended to broaden its therapeutic platform beyond peptide vaccines. SELLAS conducts its clinical trials across multiple geographies, including North America, Europe and Japan, leveraging collaborations with leading academic research centers and contract research organizations. These partnerships enable the company to advance its programs efficiently through regulatory pathways and to access patient populations in key oncology indications. The management team at SELLAS brings together seasoned executives and scientific leaders with extensive experience in oncology drug development. The company remains committed to translating its WT1-targeted immunotherapy approach into new treatment options for patients with high-unmet-need cancers.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
